| Identification | Back Directory | [Name]
GLPG0187 | [CAS]
1320346-97-1 | [Synonyms]
CS-2550
GLPG0187
GLPG 0187;GLPG-0187
GLPG0187, 98%, a broad spectrum integrin receptor antagonist with antitumor activity
L-Alanine, 3-[[2,5-dimethyl-6-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-1-piperidinyl]-4-pyrimidinyl]amino]-N-[(4-methoxyphenyl)sulfonyl]-
(S)-3-(2,5-dimethyl-6-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)piperidin-1-yl)pyrimidin-4-ylamino)-2-(4-methoxyphenylsulfonamido)propanoic acid | [Molecular Formula]
C29H37N7O5S | [MDL Number]
MFCD31381920 | [MOL File]
1320346-97-1.mol | [Molecular Weight]
595.71 |
| Chemical Properties | Back Directory | [Boiling point ]
894.7±75.0 °C(Predicted) | [density ]
1.43±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:8.0(Max Conc. mg/mL);13.43(Max Conc. mM) | [form ]
A crystalline solid | [pka]
2.86±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
GLPG-0187 is an integrin receptor antagonist which displays anti-tumor activity. | [in vivo]
Blocking αv-integrins by GLPG0187 markedly reduces their metastatic tumor growth. Bone tumor burden is significantly lower and the number of bone metastases/mouse is significantly inhibited. The progression of bone metastases and the formation of new bone metastases during the treatment period is significantly inhibited[1]. | [storage]
Store at -20°C |
|
|